# Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

> **NCT01235221** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 38 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** BIIB041 (Fampridine-SR)

## Key facts

- **NCT ID:** NCT01235221
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235221, "Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01235221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*